GlassScriptPhysician profile
Sandra Lynn Ryan
NPI 1558903583
$1,458.18
in general payments reported to CMS, 2019-2025
17 companies · $158 in 2025
The $158 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $251 · 2022: $220 · 2023: $463 · 2024: $366 · 2025: $158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $987.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $986.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $300.06 | 2022-2024 | |
| Silk Road Medical, INC. | $142.90 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Enroute Transcarotid Stent |
| Boston Scientific Corporation | $141.57 | 2025 | Watchman Flx |
| Astrazeneca Pharmaceuticals LP | $138.35 | 2023 | Farxiga |
| Abiomed | $119.91 | 2024 | Impella |
| Edwards Lifesciences Corporation | $109.33 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Abbvie INC. | $99.67 | 2021 | |
| Stemline Therapeutics INC. | $98.04 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $80.15 | 2021 | |
| Genentech USA, INC. | $71.38 | 2021 | |
| Cormedix INC. | $38.86 | 2024 | Defencath |
| Lilly USA, LLC | $31.43 | 2023-2024 | Mounjaro, Jardiance |
| Exact Sciences Corporation | $30.77 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Amgen INC. | $15.00 | 2024 | Otezla, Repatha |
| Novo Nordisk INC | $14.23 | 2023 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $13.75 | 2023 | |
| Glaxosmithkline, LLC. | $12.78 | 2023 | Shingrix, Arexvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Ryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.